To include your compound in the COVID-19 Resource Center, submit it here.
INDICATION: Acute myelogenous leukemia (AML); prostate cancer
In vitro, cell culture and mouse studies identified two dihydropyrazolopyridine-based dual CREBBP/EP300 inhibitors that could help
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury